Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype

A distinct group of colorectal carcinomas (CRCs) referred to as the “CpG island methylator phenotype” (CIMP) shows an extremely high incidence of de novo DNA methylation and may share common pathological, clinical or molecular features. However, there is limited consensus about which CpG islands (CGIs) define a CIMP, particularly in microsatellite stable (MSS) carcinomas. To study this phenotype in a systematic manner, we analyzed genome‐wide CGI DNA methylation profiles of 19 MSS CRC using methyl‐CpG immunoprecipitation (MCIp) and hybridization on 244K CGI oligonucleotide microarrays, determined KRAS and BRAF mutation status and compared disease‐related DNA methylation changes to chromosomal instability as detected by microarray‐based comparative genomic hybridization. Results were validated using mass spectrometry analysis of bisulfite‐converted DNA at a subset of 76 individual CGIs in 120 CRC and 43 matched normal tissue samples. Both genome‐wide profiling and CpG methylation fine mapping segregated a group of CRC showing pronounced and frequent de novo DNA methylation of a distinct group of CGIs that only partially overlapped with previously established classifiers. The CIMP group defined in our study revealed significant association with colon localization, either KRAS or BRAF mutation, and mostly minor chromosomal losses but no association with known histopathological features. Our data provide a basis for defining novel marker panels that may enable a more reliable classification of CIMP in all CRCs, independently of the MS status.

[1]  M. Kloor,et al.  External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS , 2019, BMC Cancer.

[2]  J. Pearson,et al.  Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas , 2019, Cellular and molecular gastroenterology and hepatology.

[3]  M. Andreu,et al.  Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy , 2018, PloS one.

[4]  M. Urioste,et al.  Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system’ , 2018, British Journal of Cancer.

[5]  R. Lothe,et al.  CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers , 2017, International journal of cancer.

[6]  A. Reeve,et al.  Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer , 2017, BMC Cancer.

[7]  M. Toyota,et al.  Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. , 2014, Gastroenterology.

[8]  Nita Ahuja,et al.  The CpG island methylator phenotype: what's in a name? , 2013, Cancer research.

[9]  D. Absher,et al.  Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape , 2013, Genome Biology.

[10]  G. Meijer,et al.  A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Thomas Lengauer,et al.  Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues , 2012, Epigenetics.

[12]  T. Hagemann,et al.  A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers , 2012, International journal of cancer.

[13]  B. Misiak,et al.  Assessment of chromosomal imbalances in CIMP-high and CIMP-low/CIMP-0 colorectal cancers , 2012, Tumor Biology.

[14]  A. Kaneda,et al.  Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes , 2010, Cancer science.

[15]  Madeeha Kamal,et al.  Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy , 2010, Breast Cancer Research.

[16]  T. Ushijima,et al.  Abstract 176: The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands , 2010 .

[17]  C. Benner,et al.  General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. , 2010, Cancer research.

[18]  P. Laird,et al.  Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling , 2009, PloS one.

[19]  M. Loda,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[20]  D. Notterman,et al.  CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer , 2008, Clinical Cancer Research.

[21]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[22]  Michael Rehli,et al.  Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. , 2006, Cancer research.

[23]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[24]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[25]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.